Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?

Publisher： Karger

E-ISSN： 1423-0232|76|2|85-90

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.2, 2008-12, pp. : 85-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite

Treating Non-Small-Cell Lung Cancer First Line with Erlotinib Monotherapy in Elderly Patients: Discussion of a Case Series

By  

Oncology Research and Treatment, Vol. 30, Iss. 10, 2007-09 ,pp. : 515-518

Karger

Access to resources Recommend Favorite

Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: A Feasible Therapeutic Option?

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 113-121

Karger

Access to resources Recommend Favorite

A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 185-189

Karger

Access to resources Recommend Favorite

Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 249-258

Karger

Access to resources Recommend Favorite